(Q39155565)

English

Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model

scientific article published on 6 May 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 September 2017

Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model (English)

1 reference

Europe PubMed Central

9 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

9 September 2017

author name string

Emily L Williams

1

1 reference

Europe PubMed Central

9 September 2017

Stuart N Dunn

2

1 reference

Europe PubMed Central

9 September 2017

Sonya James

3

1 reference

Europe PubMed Central

9 September 2017

Peter W Johnson

4

1 reference

Europe PubMed Central

9 September 2017

Martin J Glennie

6

1 reference

Europe PubMed Central

9 September 2017

Juliet C Gray

7

1 reference

Europe PubMed Central

9 September 2017

language of work or name

0 references

publication date

6 May 2013

1 reference

Europe PubMed Central

9 September 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

9 September 2017

19

1 reference

Europe PubMed Central

9 September 2017

13

1 reference

Europe PubMed Central

9 September 2017

3545-3555

1 reference

Europe PubMed Central

9 September 2017

Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Survivin and IAP proteins in cell-death mechanisms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Immunotherapy for neuroblastoma: turning promise into reality.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Anti-CD40 agonist antibodies: preclinical and clinical experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Dendritic cells dysfunction in tumour environment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Disialoganglioside directed immunotherapy of neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Therapeutic potential of immunostimulatory monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Immunogenicity of human neuroblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Emerging paradigms of T-cell co-stimulation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

T cell anergy and costimulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

The significance of lymphocytic infiltration in neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

10 September 2017

Survivin minigene DNA vaccination is effective against neuroblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

14 September 2017

Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

14 September 2017

Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

14 September 2017

Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

14 September 2017

Neuroblastoma-induced inhibition of dendritic cell IL-12 production via abrogation of CD40 expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

14 September 2017

Uncoordinate induction and differential regulation of HLA class-I and class-II expression by gamma-interferon in differentiating human neuroblastoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

15 June 2018

The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

15 June 2018

Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

21 August 2018

Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

21 August 2018

Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

21 August 2018

CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

21 August 2018

4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

21 August 2018

Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

21 August 2018

T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

4 November 2018

Properties of mouse CD40: Cellular distribution of CD40 and B cell activation by monoclonal anti-mouse CD40 antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743027

2 December 2018

Lymphoid infiltrates in neuroblastomas: Their occurrence and prognostic significance

1 reference

https://pubmed.ncbi.nlm.nih.gov/23649004

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23649004

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23649004

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23649004

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23649004

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibodies raised against the idiotype of the murine B cell lymphoma, BCL1 act primarily with heavy chain determinants

1 reference

https://pubmed.ncbi.nlm.nih.gov/23649004

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/23649004

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses

1 reference

https://pubmed.ncbi.nlm.nih.gov/23649004

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-12-3226

1 reference

Europe PubMed Central

9 September 2017

1 reference

Europe PubMed Central

9 September 2017

1 reference

Europe PubMed Central

9 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39155565&oldid=1810809132"